Fused-ring compounds and use thereof as drugs
AssigneeJapan Tobacco Inc.
InventorsHiromasa Hashimoto, Kenji Mizutani, Atsuhito Yoshida
Life of this patent
Estimating the term…
Abstract
The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hepatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.
Claims20
A compound of the formula:
- or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
A composition comprising (i) a compound of the formula:
- or a pharmaceutically acceptable salt, hydrate or solvate thereof, and (ii) a pharmaceutically acceptable carrier.
A method of treating hepatitis C in a patient, comprising administering to the patient an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt hydrate, or solvate thereof, whereby hepatitis C is treated in the patient.
A method of inhibiting hepatitis C virus polymerase in a patient, comprising administering to the patient an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt, hydrate, or solvate thereof, whereby hepatitis C virus polymerase is inhibited in the patient.
A method of inhibiting RNA-dependent RNA polymerase of hepatitis C virus in a patient, comprising administering to the patient an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt, hydrate, or solvate thereof, whereby RNA-dependent RNA polymerase of hepatitis C virus is inhibited in the patient.
Dependencies are inferred from the claim text.